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Abstract
Primary urachal adenocarcinoma is an aggressive rare cancer that often presents at advanced stages with
poor prognosis. We report this case of a 52-year-old patient with a stage-I (Mayo Clinic) primary urachal ade-
nocarcinoma with good outcomes after surgery in a 2-year follow-up period. We analyze epidemiological,
clinical and therapeutic features of this disease in the literature review.
© 2014 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V.
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Primary urachal adenocarcinoma is a rare and aggressive cancer. It
often presents at an advanced stage and has a poor prognosis. We
report the case of a 52-year-old patient with a stage I (Mayo Clinic)
primary urachal adenocarcinoma with good outcomes after surgery
with a follow-up of 2 years. We analyze epidemiological, clinical
and therapeutic features of this disease in a literature review.∗ Corresponding author. Tel.: +212 653532678.
E-mail address: imadziouziou@hotmail.com (I. Ziouziou).
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Open access under CC BY-NC-ND license.ase report
r. M.A., a 52-year-old patient, had a history of epileptic disease
reated by tegretol. He had a total intermittent hematuria and irri-
ative urinary symptoms for a month. Clinical examination was
ormal. Ultrasound revealed an echogenic mass localized in the
nterior wall of bladder. Hemoglobin was at 11.3 g/dl and renal
unction was normal. Urine was sterile at the culture.
roscan showed a 3 cm dense picture in the dome of the bladder,
nhanced after injection of contrast product, which was typical for
urachal tumor (Fig. 1 and Fig. 2).
rigid cystoscopy was performed under spinal anesthesia. It con-
rmed the presence of a solid tumor of 3–4 cm developed in the
nterior wall of the bladder. Trigon, retrotrigon, lateral walls were
ormal. Ureteral meatus were free. Then, a transurethral resection
as incompletely carried out.istology indicated a malignant tumor characterized by a glandular
roliferation including well differentiated cells sometimes isolated
ometimes grouped in polyadenoid clusters. These were covered by
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Nigure 1 CT scan of the pelvis showing echogenic mass in the bladder
ome.
seudostratified cylindrical epithelium with cytonuclear atypia. The
onnective stroma was inflammatory. Bladder’s muscle was invaded
Figs. 3 and 4).
mmunohistochemistry revealed positive marking for cytokeratin 7
nd cytokeratin 20, but negative for -catenin.
primary enteroid urachal adenocarcinoma T2 was then concluded.
rostate specific antigen (PSA) was at 0.66 ng/ml and Carcinoem-
ryonic antigen (CEA) at 2.30 ng/ml (normal value). Colonoscopy
as not found any colorectal tumor.he computed tomography (CT) of chest, abdomen and pelvis
howed neither regional nor distant metastasis.
igure 2 CT scan of the pelvis coronal view showing urachal tumor.
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digure 3 Histogram showing well differentiated adenocarcinoma
ith glandular proliferation.
median laparotomy was performed. Perioperatively, a circum-
cribed and irregular mass of 5 cm × 4 cm originated from the
rachus and extended to the dome of the bladder.
artial cystectomy, with en bloc urachectomy up to the umbilicus,
xcision of the parietal peritoneum, and bilateral pelvic lymph node
issection, were performed.
istology confirmed the diagnosis of enteroid adenocarcinoma T2
0 with negative margins.
o adjuvant treatment was proposed.he patient is still living free from disease after 2 years, as assessed
y cystoscopy and CT of chest, abdomen and pelvis performed every
months.
igure 4 Histogram showing adenocarcinoma with infiltration of
etrusor.
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Table 1 clinical staging system by Sheldon et al. [11].
Stage I Urachal cancer confined to urachal mucosa
Stage II Urachal cancer with invasion confined to urachus itself
Stage IIIA Local urachal cancer extension to bladder
Stage IIIB Local urachal cancer extension to abdominal wall
Stage IIIC Local urachal cancer extension to peritoneum
Srage IIID Local urachal cancer extension to viscera other than bladder
Stage IVA Metastatic urachal cancer to lymph nodes
Stage IVB Metastatic urachal cancer to distant sites
Table 2 clinical staging system by Mayo clinic [10].
Stage I Urachal cancer confined to the urachus and/or bladder
Stage II Urachal cancer extending beyond the muscular layer of the
urachus and/or bladder
Stage III Urachal cancer infiltrating the regional lymph nodes
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Discussion
The urachus is the embryologic remnant of allantois and the adjacent
ventral cloaca. It is a tubular structure in which lumen becomes
obliterated with the advancing age. But its patency with the urinary
bladder may persist in a small proportion of adults [1].
Urachal tumors are rare and devastating cancers of the bladder which
were first described by Hue and Jacquin in 1863. They account for
only 0.5% of all bladder malignancies, and 20–40% of primary
bladder adenocarcinomas [2–4].
Hematuria is the most common presenting symptom in about 90%
of patients [5].
The MD Anderson Cancer Center (MDACC) suggested 5 criteria
for the diagnosis of urachal cancers. These criteria include a mid-
line location of the tumor; a sharp demarcation between the tumor
and normal surface epithelium; an enteric histology; the absence
of urothelial dysplasia, cystitis cystica or cystitis glandularis transi-
tioning to the tumor; and the absence of a primary adenocarcinoma
of another origin [6,7].
Wheeler and Hill in 1954 proposed 5 criteria: location in the bladder
dome or anterior wall; invasion of the bladder wall from outside to
inside; absence of cystitis cystica or cystitis glandularis; presence
of embryonic remnants; absence of a primary adenocarcinoma of
another origin [8]. All of these criteria were present in our reported
case.
Immunohistochemistry may help in the distinction between primary
and secondary adenocarcinoma.
In primary adenocarcinomas of the bladder, CK7 and CK20 are
positive in contrast with colonic adenocarcinomas that express only
CK20 [5]. A diffuse nuclear immunoreactivity for -catenin would
militate against the diagnosis of urachal adenocarcinoma [9].
Partial cystectomy with en bloc urachectomy up to the umbilicus is
considered the gold standard for the treatment of urachal carcinoma
when the disease is surgically resectable. Partial cystectomy is per-
formed to ensure negative margins. En bloc resection of the urachal
ligament and umbilicus is recommended because tumors can occur
anywhere along the urachus, including at the umbilicus (7%) [4].
If the urachus is transected during surgery, spillage of the tumor
containing fluid into the peritoneal cavity can increase the risk of
relapse [10,11].
The open surgical approach is favored actually due to the lack of
long-term data on either laparoscopic or robotic surgeries [12–14].
In 1984, Sheldon et al. [11] have proposed a system for clinical stag-
ing of urachal adenocarcinoma. In this system, early stage urachal
cancers are localized to the urachal mucosa, whereas late stage dis-
ease involves local structures, like the bladder, abdominal wall or
peritoneum, and metastases to regional lymph nodes or distant sites
(Table 1). The Mayo clinic has suggested recently a more simplified
system (Table 2) [10]. But none of them are validated.There is currently no standard adjuvant or metastatic chemother-
apy protocol for the treatment of urachal adenocarcinoma. The
choice of protocols has been based largely on case reports and singleStage IV Urachal cancer infiltrating the non-regional lymph nodes or
other distant sites
nstitutional experiences. The results of the phase II trial of gemc-
tabine + cisplatin + 5-FU might further define a treatment standard
or this disease [4].
ecent case reports show the benefit of combined chemotherapy
n isolated cases of urachal cancers, most of them adenocarcino-
as: the association of 5-FU, cisplatin or oxaliplatin, irinotecan
nd bevacizumab in different combinations demonstrated usually a
artial and limited response [15–18].
iefker-Radtke et al. [7] have reported a 46-month overall sur-
ival from diagnosis of 42 patients (including 7 with metastasis,
nd 35 with resectable disease). Forty percent of them survive for
years. Of the resected cases, 46% remain disease-free with a
edian follow-up of 31 months. Long-term survival was associated
ith negative surgical margins (P = 0.004) and absence of nodal
nvolvement (P = 0.01).
onflict of interest
here is no conflict of interest.
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